Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment
Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment
Sponsor: PriCara, Unit of Ortho-McNeil, Inc.
Listed as NCT00204698, this PHASE2/PHASE3 trial focuses on Laryngopharyngeal Reflux and remains completed. Sponsored by PriCara, Unit of Ortho-McNeil, Inc., it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Aug 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PriCara, Unit of Ortho-McNeil, Inc.
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Salt Lake City, United States